Recent literature supports the notion that stem cells have the ability to directly modulate pain.
Nearly two decades’ worth of experience in the veterinary field led to the formation of Personalized Stem Cells, a human adipose-derived stem cell company.
Personalized Stem Cells announces licensing agreement for its allogeneic stem cell program including COVID-19 therapy.
Personalized Stem Cells secured $2.5 million during a Series A round of financing in spite of the current economic crisis.
When COVID-19 was declared a global pandemic, we at Personalized Stem Cells felt called to action to manufacture and provide potentially life-saving stem cell therapy to patients ill with COVID-19.
Personalized Stem Cells has completed enrollment of their first FDA approved stem cell clinical trial.
Personalized Stem Cells, Inc. provides stem cell processing services to doctors for their patients who are participating in FDA approved clinical trials
Personalized Stem Cells is committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.
Personalized Stem Cells (PSC) recently received FDA approval to treat COVID-19 patients with stem cells in an upcoming clinical trial.
The COVID-19 pandemic has changed our way of life these past few months. The Personalized Stem Cells team has been working hard to continue manufacturing stem cell doses for current and potential clinical trial participants.